Trulicity vs Mounjaro: Diabetes Management Comparison
Compare Trulicity and Mounjaro for type 2 diabetes using product-specific dose schedules, completed cardiovascular outcomes evidence, storage and access.
Overview: Trulicity and Mounjaro for Diabetes
Trulicity’s current label covers type 2 diabetes from age 10 and MACE-risk reduction in adults with type 2 diabetes with established cardiovascular disease or multiple risk factors. It contains dulaglutide, a GLP-1 agonist; Mounjaro contains the GIP/GLP-1 agonist tirzepatide. Neither product’s diabetes evidence makes it an approved obesity brand, and receptor count alone does not establish an individual outcome.
The current Mounjaro label covers glycemic control in type 2 diabetes from age 10 and cardiovascular-event risk reduction in adults with type 2 diabetes at high cardiovascular risk. Zepbound contains tirzepatide but has adult weight-management and moderate-to-severe obstructive-sleep-apnea indications in adults with obesity. Approval of one brand does not automatically transfer its indication to another.
Mechanism of Action: How They Work
Both affect glucose regulation and appetite through incretin receptors. Different targets do not establish a universal efficacy or tolerability ranking.
Trulicity (Dulaglutide): Single GLP-1 Agonist
Trulicity’s current label covers type 2 diabetes from age 10 and MACE-risk reduction in adults with type 2 diabetes with established cardiovascular disease or multiple risk factors. It contains dulaglutide, a GLP-1 agonist; Mounjaro contains the GIP/GLP-1 agonist tirzepatide. Neither product’s diabetes evidence makes it an approved obesity brand, and receptor count alone does not establish an individual outcome.
Mounjaro (Tirzepatide): Dual GLP-1/GIP Agonist
Semaglutide activates the GLP-1 receptor; tirzepatide activates GIP and GLP-1 receptors. Both can improve glucose regulation and reduce appetite. Dual receptor activity is a mechanistic distinction, not proof of better outcomes for every person or of preserved muscle. This comparison concerns the named weekly injections unless another formulation is specified.
Clinical Efficacy: A1C Reduction and Glucose Control
Use a defined study and comparator rather than unmatched HbA1c ranges.
Trulicity A1C Reduction
Trulicity’s dose-ranging label study enrolled 1,842 adults with type 2 diabetes on metformin. At 36 weeks, the label’s intention-to-treat analysis with its specified imputation showed mean losses of 3.0, 3.8 and 4.6 kg at 1.5/3/4.5 mg. These are kilograms, not percentages, and not a Mounjaro comparison. Both glucose and weight changed favorably in this defined population; cross-trial ranges do not establish a fixed two-to-threefold difference.
Mounjaro A1C Reduction
SURPASS-2 studied 1,879 adults with type 2 diabetes taking metformin for 40 weeks. Weekly tirzepatide 5/10/15 mg produced larger average HbA1c and weight reductions than semaglutide 1 mg. HbA1c changes were −2.01/−2.24/−2.30 versus −1.86 percentage points. This is a useful direct diabetes comparison, not a comparison against every semaglutide dose or formulation.
SURPASS-2 used semaglutide, not Trulicity. Its positive findings do not establish superiority over every dulaglutide dose.
Weight Loss: Additional Metabolic Benefit
Weight changes occur in diabetes trials, but weight percentages and kilograms are not interchangeable.
Trulicity Weight Loss
Trulicity’s dose-ranging label study enrolled 1,842 adults with type 2 diabetes on metformin. At 36 weeks, the label’s intention-to-treat analysis with its specified imputation showed mean losses of 3.0, 3.8 and 4.6 kg at 1.5/3/4.5 mg. These are kilograms, not percentages, and not a Mounjaro comparison. Both glucose and weight changed favorably in this defined population; cross-trial ranges do not establish a fixed two-to-threefold difference.
Mounjaro Weight Loss
SURPASS-2 studied 1,879 adults with type 2 diabetes taking metformin for 40 weeks. Weekly tirzepatide 5/10/15 mg produced larger average HbA1c and weight reductions than semaglutide 1 mg. HbA1c changes were −2.01/−2.24/−2.30 versus −1.86 percentage points. This is a useful direct diabetes comparison, not a comparison against every semaglutide dose or formulation.
Dosing Schedules and Titration
Both are weekly injections, with different strengths, age-specific maxima and devices.
Trulicity (Dulaglutide) Dosing
Trulicity starts at 0.75 mg once weekly. Adult escalation to 1.5 mg and, if needed, further 1.5-mg steps requires at least four weeks at the preceding dose; the adult maximum is 4.5 mg. From age 10, the pediatric maximum is 1.5 mg. Escalating every two weeks is not the current label schedule. Use the supplied single-dose pen instructions rather than transfer technique or volumes from another product.
Mounjaro (Tirzepatide) Dosing
Mounjaro starts at 2.5 mg once weekly; increases in 2.5-mg steps require additional glycemic control and at least four weeks at the current dose. Zepbound starts at 2.5 mg weekly for four weeks, then 5 mg; later increases require at least four weeks at the current dose, considering response and tolerability. Adult maximum is 15 mg; Mounjaro’s pediatric maximum is 10 mg. Zepbound weight-management maintenance doses are 5, 10 or 15 mg, whereas its OSA maintenance doses are 10 or 15 mg. A maximum is not a target for everyone.
Side Effects and Tolerability
Similar GI symptom types do not establish equal rates or a lower-efficacy safety advantage.
Common Side Effects (Both Medications)
Nausea, vomiting, diarrhea and abdominal symptoms occur; response to escalation varies and symptoms are not guaranteed to resolve in two to four weeks.
Serious Warnings and Product-Specific Risks
Both have formal MTC/MEN2 and serious-hypersensitivity contraindications, not merely a general “thyroid history” caution. Their labels address pancreatitis, gallbladder disease, severe GI effects, dehydration-related kidney injury, hypoglycemia with insulin/SU and other precautions. Review the exact label and relevant history.
Cost and Insurance Coverage
Compare a current itemized quote for the exact product, dose, device and prescription indication. Original estimates of roughly $800–$1,500 monthly for branded injections were historical examples, not current offers. Coverage, deductibles, quantity limits and manufacturer-program eligibility vary; commercial savings cards generally have exclusions and do not guarantee a $25 copay or uninsured access. Medicare/Medicaid decisions depend on the covered indication and applicable rules rather than a blanket exclusion of every use.
Retail Pricing (Without Insurance)
Old $900–$1,150 retail examples do not establish a current matched quote or universal value advantage.
Insurance Coverage
Choose around the actual treatment goal, approved indication, prior response, risks, available formulations and sustainable access. More average weight loss does not necessarily mean the best option for an individual. Type 2 diabetes, established cardiovascular disease, CKD, obesity or OSA can change which product-specific evidence matters. An arbitrary three-month percentage threshold or cost-first ladder does not settle every decision.
Copay Assistance Programs
Manufacturer savings cards have product- and insurance-specific terms and exclusions. Do not assume all patients pay $10–$35 or that coverage implies eligibility for commercial coupons.
Cardiovascular Benefits and Safety
REWIND established favorable dulaglutide cardiovascular evidence and supports Trulicity’s specified adult indication. Completed SURPASS-CVOT directly compared tirzepatide up to 15 mg with dulaglutide 1.5 mg in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. The primary MACE comparison met noninferiority, not superiority (HR 0.92, 95.3% CI 0.83–1.01). Mounjaro’s current label includes its specified adult CV indication. These findings do not compare dulaglutide 4.5 mg against every tirzepatide regimen.
Trulicity Cardiovascular Benefit
Trulicity’s current label covers type 2 diabetes from age 10 and MACE-risk reduction in adults with type 2 diabetes with established cardiovascular disease or multiple risk factors. It contains dulaglutide, a GLP-1 agonist; Mounjaro contains the GIP/GLP-1 agonist tirzepatide. Neither product’s diabetes evidence makes it an approved obesity brand, and receptor count alone does not establish an individual outcome.
Mounjaro Cardiovascular Benefit
The current Mounjaro label covers glycemic control in type 2 diabetes from age 10 and cardiovascular-event risk reduction in adults with type 2 diabetes at high cardiovascular risk. Zepbound contains tirzepatide but has adult weight-management and moderate-to-severe obstructive-sleep-apnea indications in adults with obesity. Approval of one brand does not automatically transfer its indication to another.
REWIND established favorable dulaglutide cardiovascular evidence and supports Trulicity’s specified adult indication. Completed SURPASS-CVOT directly compared tirzepatide up to 15 mg with dulaglutide 1.5 mg in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. The primary MACE comparison met noninferiority, not superiority (HR 0.92, 95.3% CI 0.83–1.01). Mounjaro’s current label includes its specified adult CV indication. These findings do not compare dulaglutide 4.5 mg against every tirzepatide regimen.
Quick Comparison Table
| Question | Product or finding | Clinical limit |
|---|---|---|
| Mechanism | Dulaglutide GLP-1 versus tirzepatide GIP/GLP-1 | No fixed comparative efficacy ratio |
| Dose | Adult maxima 4.5 mg versus 15 mg; pediatric 1.5 mg versus 10 mg | Both use at least four-week escalation intervals |
| CV | REWIND and completed SURPASS-CVOT | Noninferiority is not superiority |
| Handling | Trulicity single-dose pens: 14 days at room temperature; Mounjaro presentation-specific | No universal opened-pen 30-day rule |
Which Should You Choose?
Choose around the actual treatment goal, approved indication, prior response, risks, available formulations and sustainable access. More average weight loss does not necessarily mean the best option for an individual. Type 2 diabetes, established cardiovascular disease, CKD, obesity or OSA can change which product-specific evidence matters. An arbitrary three-month percentage threshold or cost-first ladder does not settle every decision.
Choose Trulicity If:
Trulicity may fit its diabetes/CV indication, prior adequate response, tolerability, device preference and access; longer use history alone is not universal safety proof.
Choose Mounjaro If:
The current Mounjaro label covers glycemic control in type 2 diabetes from age 10 and cardiovascular-event risk reduction in adults with type 2 diabetes at high cardiovascular risk. Zepbound contains tirzepatide but has adult weight-management and moderate-to-severe obstructive-sleep-apnea indications in adults with obesity. Approval of one brand does not automatically transfer its indication to another.
Choose around the actual treatment goal, approved indication, prior response, risks, available formulations and sustainable access. More average weight loss does not necessarily mean the best option for an individual. Type 2 diabetes, established cardiovascular disease, CKD, obesity or OSA can change which product-specific evidence matters. An arbitrary three-month percentage threshold or cost-first ladder does not settle every decision.
Trulicity’s label permits each single-dose pen up to a total of 14 days at room temperature no higher than 30°C. Mounjaro’s label distinguishes single-dose pens/vials (up to a total of 21 days no higher than 30°C) from multidose vials and single-patient KwikPens (separate 30-day room-temperature, first-use and four-weekly-dose limits). A single-dose device is used once, not retained as an opened multidose pen. Do not freeze either; follow the actual presentation and any earlier discard condition.
A calculator supplies arithmetic, not a first-line treatment recommendation.
Related reading: tirzepatide dosage calculator.
Frequently Asked Questions
Both have effective diabetes-treatment evidence. A comparison must specify dose, population and endpoint; separate HbA1c ranges do not establish one fixed advantage over every dulaglutide dose. Completed cardiovascular outcomes data also now matter.
Weight fell in trials of both products, but dulaglutide’s label dose-ranging result is in kilograms, not a fixed three-to-five percent promise. Unmatched diabetes or obesity studies do not establish a two-to-threefold individual difference.
A prescriber may assess a change, but weekly injections are not automatically interchangeable. There is no universal conversion or washout calendar; review the actual last dose, interruption, symptoms, other glucose medicines and product-specific plan.
Trulicity contains dulaglutide, a GLP-1 agonist; Mounjaro contains tirzepatide, a GIP/GLP-1 agonist. Approved indications, doses, devices and evidence differ beyond the receptor count.
Trulicity single-dose pens have a total room-temperature limit of 14 days no higher than 30°C. Mounjaro singles have a 21-day limit; its multidose vial and KwikPen have separate 30-day/first-use/four-dose instructions. A single-use device is not kept as an opened multidose pen. Follow the exact package and any earlier discard condition.
Coverage and authorization depend on the product, diagnosis and plan. Manufacturer commercial savings cards have their own eligibility rules and are not proof of coverage or a government-program benefit.
Both can cause GI symptoms, but unmatched rates or lower average efficacy do not prove fewer side effects. Review actual product warnings, contraindications, prior response and symptoms rather than assume universal tolerability or fixed recovery time.
Both labels address acute pancreatitis and other relevant risks. A prior history needs individualized review; it is not interchangeable with every gallbladder diagnosis or a complete list of formal contraindications. Severe or persistent abdominal pain warrants prompt assessment.